Somewhere in a steel tank filled with liquid nitrogen in Scottsdale, Arizona, roughly 230 human bodies float upside down at minus 196 degrees Celsius, preserved in a state their caretakers hope is not permanent death but rather an indefinitely long pause. The patients — and the organizations that froze them insist on calling them patients — are clients of the Alcor Life Extension Foundation, the world’s most prominent cryonics facility. They paid as much as $220,000 for the chance, however slim, that future technology might one day revive them.
It sounds like science fiction. For decades, mainstream science treated it that way.
But something has shifted. A growing body of research in brain preservation, connectomics, and molecular biology is lending unexpected scientific credibility to at least part of the cryonics premise — not that frozen people will wake up tomorrow, but that the structural information encoded in a preserved brain might survive the process of death and freezing far better than anyone previously assumed. And that shift is attracting serious money, prominent researchers, and a new wave of startups determined to move brain preservation from the fringes of transhumanism into something resembling legitimate medical science.
As Futurism reported in a detailed examination of the field, cryonics has long occupied an awkward space between scientific ambition and cultural ridicule. The basic idea is straightforward: if the biological structures that encode memory, personality, and identity can be preserved at the moment of death, then some future civilization with sufficiently advanced technology could theoretically repair the damage caused by both the disease that killed the person and the preservation process itself. The problem, historically, has been that freezing human tissue causes catastrophic ice crystal formation that shreds cells from the inside out.
That problem hasn’t been fully solved. But it’s been dramatically reduced.
Modern cryopreservation uses vitrification — replacing blood and other fluids with cryoprotectant chemicals that allow tissue to solidify into a glass-like state rather than crystallizing into ice. The technique, refined over decades, has already proven its worth in mainstream medicine. Thousands of human embryos are vitrified and successfully thawed every year in fertility clinics worldwide. Organs are another matter entirely, given their size and complexity, but even there, progress has been striking. In 2023, researchers at the University of Minnesota successfully vitrified and rewarmed a rat kidney, then transplanted it into a living rat, where it functioned. A whole organ, frozen to cryogenic temperatures, brought back.
That result electrified the cryonics community and caught the attention of researchers who had previously kept their distance. The gap between preserving a single kidney and preserving an entire human brain — let alone reviving the person it belonged to — remains enormous. Nobody disputes that. But the direction of progress is hard to ignore.
The brain is the central obsession. Everything else — the body, the organs — is theoretically replaceable, at least in the speculative future that cryonics proponents envision. What matters is whether the connectome, the intricate web of roughly 100 trillion synaptic connections that constitutes a person’s neural architecture, survives the preservation process in a readable state. Recent electron microscopy studies have shown that vitrified brain tissue retains synaptic structure with remarkable fidelity. The wiring diagram appears to survive. Whether that diagram is sufficient to reconstruct a conscious mind is a question that sits at the intersection of neuroscience, philosophy, and faith.
Robert McIntyre is perhaps the most visible figure pushing brain preservation toward scientific respectability. His company, Nectome, made headlines — and generated controversy — when it won the Brain Preservation Foundation’s prize in 2018 for preserving a pig brain so well that every synapse was visible under electron microscopy. The method used, aldehyde-stabilized cryopreservation, involves chemically fixing the brain with glutaraldehyde before vitrification. It produces exquisite structural preservation. It also kills the brain’s cells in the process, which means revival, if it ever happens, would require not just rewarming but wholesale molecular reconstruction — a technology that doesn’t exist and may never exist.
Nectome’s early pitch drew fierce backlash. The company initially explored the idea of performing the procedure on terminally ill patients while they were still alive, under physician-assisted death laws. MIT severed a research collaboration. Nectome stepped back from that approach, but the episode illustrated the intense ethical fault lines running through brain preservation research.
And yet the scientific work continued. As Futurism noted, a growing number of neuroscientists now take seriously the proposition that long-term memory is encoded in the physical structure of synapses and neural circuits rather than in ongoing electrical activity. If that’s true — and evidence from studies of hibernating animals, organisms that survive freezing in nature, and patients who’ve recovered full neurological function after prolonged cardiac arrest all point in that direction — then a well-preserved brain might retain its owner’s identity even in the absence of biological life.
The business side of cryonics has historically been modest, almost amateurish. Alcor operates as a nonprofit. The Cryonics Institute in Michigan charges as little as $28,000 for whole-body preservation, funded in many cases through life insurance policies. Staff sizes are small. The organizations have sometimes struggled with quality control, public relations, and the logistical nightmare of deploying preservation teams to members who die in remote locations or without warning.
That’s changing too. New companies are entering the space with venture capital backing and Silicon Valley sensibilities. Tomorrow Biostasis, based in Berlin, launched in 2020 as Europe’s first cryonics company and has been growing its membership steadily. Southern Cryonics opened a facility in rural New South Wales, Australia. In the United States, a handful of startups are working on improved vitrification protocols, faster standby response times, and the kind of operational professionalism that the field has lacked.
The money flowing in isn’t trivial. Sam Altman, the CEO of OpenAI, reportedly paid $10,000 to join Nectome’s waiting list in 2018. Peter Thiel has spoken publicly about his interest in life extension, and several prominent tech executives have cryonics arrangements, though most prefer not to discuss them. The cultural stigma remains powerful. Signing up for cryopreservation is still, in most social circles, an invitation to ridicule.
But the demographics of cryonics membership are shifting. Alcor’s membership has grown from around 1,000 a decade ago to over 1,400 today. The Cryonics Institute reports similar growth. Members skew younger than they used to, and the gender imbalance — historically the field was overwhelmingly male — is slowly narrowing. Many new members are in their 30s and 40s, often working in technology or science, and they frame the decision not as a guarantee but as a Pascal’s Wager: the cost is finite, the potential upside is infinite, and the alternative is certain oblivion.
Critics aren’t hard to find. Most mainstream neuroscientists and physicians remain deeply skeptical, not necessarily of the preservation science itself but of the revival premise. Dr. Michael Bhatt, a neurologist at UCLA, told Scientific American in a recent interview that preserving the structure of the brain is not the same as preserving the mind. “We don’t even know what consciousness is,” he said. “The idea that you could reconstruct it from a frozen connectome assumes we’ve solved problems we haven’t even properly defined.”
There’s also the problem of time. Cryonics organizations must remain solvent and operational for decades, possibly centuries, to fulfill their promises. Alcor has existed since 1972, which is impressive for a nonprofit in a niche field, but it’s a blink in the timeframe its members are betting on. Wars, economic collapses, natural disasters, simple institutional decay — any of these could interrupt the continuous supply of liquid nitrogen that keeps those steel tanks at temperature. A prolonged power outage wouldn’t be immediately fatal to the preserved patients, since the tanks are passively cooled, but the long-term institutional risks are real and largely uninsurable.
The legal and ethical questions are equally thorny. Cryopreservation can only legally begin after a person is declared dead, which means the very damage that cryonics aims to reverse — the cascade of cellular destruction that follows cardiac arrest — has already begun by the time the preservation team starts work. The best outcomes occur when a standby team is present at the moment of death and can begin cooling and administering cryoprotectants within minutes. The worst outcomes involve patients who die unexpectedly, aren’t discovered for hours, or are in jurisdictions where autopsies are required before the body can be released.
Some advocates have pushed for the right to begin preservation before legal death, particularly for terminally ill patients who face certain and imminent death. This is where the conversation veers into territory that makes most bioethicists profoundly uncomfortable. Oregon and several other states allow physician-assisted death, but no jurisdiction currently permits a medical procedure whose explicit purpose is to kill the patient’s body in order to preserve the brain. The conceptual distinction between “ending suffering” and “attempting to preserve identity for future revival” is significant, and the legal frameworks haven’t begun to address it.
Meanwhile, the science of connectomics — mapping the brain’s wiring at the level of individual synapses — is advancing independently of cryonics and for entirely different reasons. The NIH’s BRAIN Initiative, launched in 2013, has poured billions of dollars into understanding neural circuitry. Google and the Allen Institute for Brain Science have produced detailed connectome maps of fruit fly brains and portions of mouse brains. A complete map of a human brain remains far off, but the tools to read one are improving at a pace that would have seemed implausible twenty years ago.
This matters for cryonics because the revival scenario most commonly discussed doesn’t involve simply thawing a frozen brain and restarting it. Instead, proponents envision a future technology — possibly involving advanced nanotechnology, molecular-scale robots, or whole-brain emulation via scanning — that could read the preserved connectome and either repair the biological brain or upload its information into a digital or synthetic substrate. It’s speculative. Wildly so. But it’s speculative in a way that tracks with observable technological trends rather than contradicting known physics.
The philosophical questions may ultimately prove harder than the technical ones. If a future civilization scans your preserved brain and creates a digital copy that has all your memories and personality traits, is that copy you? Or is it a new entity that merely believes it’s you? Philosophers have debated personal identity for centuries without resolution, and cryonics forces the question into uncomfortably concrete territory. For many cryonics members, the answer is pragmatic rather than philosophical: even a copy is better than nothing.
Not everyone in the preservation community agrees on methods. A faction favors chemical fixation — the aldehyde approach — arguing that it produces superior structural preservation and doesn’t require the complex logistics of cryogenic storage. A fixed brain could theoretically be stored at room temperature in a block of resin, eliminating the need for liquid nitrogen and the institutional risks that come with it. The tradeoff is that chemical fixation is even more definitively lethal to biological cells than vitrification, pushing the revival timeline further into the speculative future. The debate between these camps is technical, passionate, and unresolved.
There’s a generational element to all of this. The founders of the cryonics movement — people like Robert Ettinger, who published The Prospect of Immortality in 1962 — were dreamers operating almost entirely on hope. The current generation is more empirical, more cautious in its claims, and more focused on producing peer-reviewed evidence that preservation actually works at the structural level. They’re also more willing to acknowledge what they don’t know.
The question isn’t whether cryonics will work. Nobody can answer that today. The question is whether the information that makes you you can survive the transition from living brain to preserved brain with enough fidelity that some future technology could, in principle, do something with it. And on that narrower question, the evidence is more encouraging than it’s ever been.
So here’s where things stand. The science of brain preservation is real and advancing. The business of cryonics is growing and professionalizing. The ethical and philosophical debates remain largely unresolved. And in those steel tanks in Arizona, Michigan, and now Europe and Australia, a small but growing number of people have placed their bets — not on certainty, but on the possibility that death, as we currently define it, may not be as permanent as it seems.
Whether that bet pays off is a question for a future none of us can predict. But for the first time in the field’s history, it’s a question that serious scientists are willing to ask out loud.
WebProNews is an iEntry Publication